BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 27179727)

  • 1. Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.
    Berger JS; Katona BG; Jones WS; Patel MR; Norgren L; Baumgartner I; Blomster J; Mahaffey KW; Held P; Millegård M; Heizer G; Reist C; Fowkes FG; Hiatt WR
    Am Heart J; 2016 May; 175():86-93. PubMed ID: 27179727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
    Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
    Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.
    Hiatt WR; Fowkes FG; Heizer G; Berger JS; Baumgartner I; Held P; Katona BG; Mahaffey KW; Norgren L; Jones WS; Blomster J; Millegård M; Reist C; Patel MR;
    N Engl J Med; 2017 Jan; 376(1):32-40. PubMed ID: 27959717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
    Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease.
    Jones WS; Baumgartner I; Hiatt WR; Heizer G; Conte MS; White CJ; Berger JS; Held P; Katona BG; Mahaffey KW; Norgren L; Blomster J; Millegård M; Reist C; Patel MR; Fowkes FG;
    Circulation; 2017 Jan; 135(3):241-250. PubMed ID: 27840336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
    Bonaca MP; Bhatt DL; Storey RF; Steg PG; Cohen M; Kuder J; Goodrich E; Nicolau JC; Parkhomenko A; López-Sendón J; Dellborg M; Dalby A; Špinar J; Aylward P; Corbalán R; Abola MTB; Jensen EC; Held P; Braunwald E; Sabatine MS
    J Am Coll Cardiol; 2016 Jun; 67(23):2719-2728. PubMed ID: 27046162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
    Bonaca MP; Bhatt DL; Braunwald E; Cohen M; Steg PG; Storey RF; Held P; Jensen EC; Sabatine MS
    Am Heart J; 2014 Apr; 167(4):437-444.e5. PubMed ID: 24655690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
    Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial.
    Hopley CW; Kavanagh S; Patel MR; Ostrom C; Baumgartner I; Berger JS; Blomster JI; Fowkes FGR; Jones WS; Katona BG; Mahaffey KW; Norgren L; Rockhold FW; Hiatt WR
    Vasc Med; 2019 Oct; 24(5):422-430. PubMed ID: 31339474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.
    Norgren L; Patel MR; Hiatt WR; Wojdyla DM; Fowkes FGR; Baumgartner I; Mahaffey KW; Berger JS; Jones WS; Katona BG; Held P; Blomster JI; Rockhold FW; Björck M;
    Eur J Vasc Endovasc Surg; 2018 Jan; 55(1):109-117. PubMed ID: 29273390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroke in Patients With Peripheral Artery Disease.
    Kolls BJ; Sapp S; Rockhold FW; Jordan JD; Dombrowski KE; Fowkes FGR; Mahaffey KW; Berger JS; Katona BG; Blomster JI; Norgren L; Abramson BL; Leiva-Pons JL; Prieto JC; Sokurenko G; Hiatt WR; Jones WS; Patel MR
    Stroke; 2019 Jun; 50(6):1356-1363. PubMed ID: 31092165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.
    Olivier CB; Mulder H; Hiatt WR; Jones WS; Fowkes FGR; Rockhold FW; Berger JS; Baumgartner I; Held P; Katona BG; Norgren L; Blomster J; Patel MR; Mahaffey KW
    JAMA Cardiol; 2019 Jan; 4(1):7-15. PubMed ID: 30540355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial.
    Gutierrez JA; Mulder H; Jones WS; Rockhold FW; Baumgartner I; Berger JS; Blomster JI; Fowkes FGR; Held P; Katona BG; Mahaffey KW; Norgren L; Hiatt WR; Patel MR
    JAMA Netw Open; 2018 Nov; 1(7):e185239. PubMed ID: 30646395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investigator-Initiated trial.
    de Waha A; Sandner S; von Scheidt M; Boening A; Koch-Buettner K; Hammel D; Hambrecht R; Danner BC; Schöndube FA; Goerlach G; Fischlein T; Schmoeckel M; Oberhoffer M; Schulz R; Walther T; Ziegelhöffer T; Knosalla C; Schönrath F; Beyersdorf F; Siepe M; Attmann T; Misfeld M; Mohr FW; Sievers HH; Joost A; Putman LM; Laufer G; Hamm C; Zeymer U; Kastrati A; Radke PW; Lange R; Cremer J; Schunkert H
    Am Heart J; 2016 Sep; 179():69-76. PubMed ID: 27595681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
    Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
    Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Trial Comparing the Effects of Ticagrelor Versus Clopidogrel on Myocardial Perfusion in Patients With Coronary Artery Disease.
    Pelletier-Galarneau M; Hunter CRRN; Ascah KJ; Beanlands RSB; Dwivedi G; deKemp RA; Chow BJW; Ruddy TD
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28465300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).
    Bonaca MP; Goto S; Bhatt DL; Steg PG; Storey RF; Cohen M; Goodrich E; Mauri L; Ophuis TO; Ruda M; Špinar J; Seung KB; Hu D; Dalby AJ; Jensen E; Held P; Morrow DA; Braunwald E; Sabatine MS
    Circulation; 2016 Sep; 134(12):861-71. PubMed ID: 27576775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
    Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM
    Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease.
    Szarek M; Hess C; Patel MR; Jones WS; Berger JS; Baumgartner I; Katona B; Mahaffey KW; Norgren L; Blomster J; Rockhold FW; Hsia J; Fowkes FGR; Bonaca MP
    J Am Heart Assoc; 2022 Jun; 11(11):e025504. PubMed ID: 35621222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.